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The characteristics of 30 carriers with occult hepatitis B virus (HBV) infection (OBI) were compared with those
of 30 individuals diagnosed as being HBV carriers at the time of blood donation, 60 asymptomatic carriers, and 60
chronic hepatitis patients. The prevalence of genotype C was significantly higher in carriers with OBIs than in any
other HBsAg-positive (HBsAg) group (P < 0.001). Specific amino acid substitutions in the regions from amino
acids 117 to 121 and amino acids 144 to 147 located in the major hydrophilic region of the S gene were associated
with carriers with OBIs (P<0.01 for carriers with OBIs versus HBsAg donors, carriers with OBIs versus HBsAg
asymptomatic carriers, and carriers with OBIs versus HBsAg chronic hepatitis patients). G145R was the major
variation in the HBV isolates responsible for local occult HBV infections.
The introduction of screening for hepatitis B virus (HBV)
surface antigen (HBsAg) has reduced the risk of overt HBV
transfusion-transmitted infections (TTIs), although transfu-
sion-transmitted infections continue to occur. In particular,
occult hepatitis B virus infection (OBI) poses a threat to the
blood supply. Individuals with OBIs are defined as those in
whom viral DNA is detected in liver or blood by nested PCR
or real-time PCR but in whom HBsAg is undetectable in serum
by current commercial HBsAg assays. Occult HBV infection
status can be associated with mutant viruses undetectable by
current HBsAg assays (10, 11, 15, 17, 28), but it may also be
due to the suppression of viral replication and gene expression
and virus secretion (2, 7, 13, 23). The presence of an OBI can
occur after recovery from an infection but anti-HBs remains
present (21, 25, 29) or anti-HBc is the only marker (12), or an
OBI may even be the state in which no antibody makers may be
present. The presence of HBV is detectable only if a highly
sensitive method is used (8). The viral load is mostly less than
104 IU/ml (4) and is often less than 200 IU/ml (24). Indeed,
immunosuppressed organ or bone marrow transplant recipi-
ents with anti-HBs or anti-HBc have been shown to be infec-
tious. To prevent the transmission of such infections, screening
for anti-HBc is not 100% effective. Additionally, screening of
pooled blood donations, a common practice in blood banks,
also decreases the sensitivities of the assays used (3). Finally, if
an HBV nucleic acid test (NAT) is used, it needs to be ex-
tremely sensitive to eliminate HBV DNA-containing units (1).
In countries where HBV is endemic, such as China, research
into OBI is limited by the lack of a suitable method for screen-
ing large numbers of samples. HBV NAT is procedurally cum-
bersome and incurs high costs. Thus, given these constraints,
the use of an anti-HBc alone (serum antibodies against HBV
core antigen in isolation) as a marker for OBI was investigated
in the study described here, given that it may be a possible
marker of infection (27), with one study citing an OBI detec-
tion rate of between 5 and 10% for patients who tested positive
for anti-HBc as the sole marker of HBV infection (4). The
clinical epidemiology of blood donor OBIs is not known in
China, and the present study attempted to determine the clin-
ical and molecular characteristics of these infections in the
context of other cohorts of HBV carriers.
MATERIALS AND METHODS
Serological tests for study subjects. A total of 19,518 blood samples were
collected from blood donors at the Xiamen Blood Service, Fujian Province,
China, from 18 July 2007 to 27 August 2008. All samples initially tested negative
by a rapid test for HBsAg. This was a colloidal gold immunoassay (Wantai Ltd,
Beijing, China) with a lower detection limit of 2 IU. To minimize the occurrence
of false-negative results, three different commercial assays (Murex [version 3]
enzyme-linked immunosorbent assay [ELISA; Abbott Murex, Dartford, United
Kingdom]; Wantai Company [Beijing, China] ELISA; Xinchuang ELISA [InTec,
Xiamen, China]) were used for further screening for HBsAg. Samples with a
positive result by any one assay were considered to be HBsAg positive. For
specimens that were HBsAg negative, two additional commercial HBsAg assays
(Hepanostika HBsAg Ultra [bioMe´rieux, Marcy l’Etoile, France]; Monolisa Ag
HBs Ultra [Bio-Rad, Marnes La Coquette, France]) were used to confirm the
HBsAg status of the blood samples. The sensitivities of the five HBsAg assays
ranged from 0.03 to 0.2 IU/ml. Testing for HBeAg, anti-HBs, and anti-HBc was
performed by the Wantai ELISA. Anti-HIV, anti-Treponema pallidum (the syph-
ilis spirochete), and anti-hepatitis C virus (anti-HCV) antibodies were detected
by the use of the Murex ELISA products. All assays were performed according
to the manufacturers’ instructions and were performed on an ELISASTARlet
automated system (Hamilton, Bonaduz, Switzerland).
HBV DNA analyses. All specimens positive for anti-HBc alone were tested for
HBV DNA. Viral DNA was extracted from 300 l of plasma by using a QIAamp
DNA blood kit (Qiagen, Hilden, Germany). Six different primers pairs (Table 1)
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were utilized in the nested PCRs (which were performed by the procedures
described in footnote a of Table 1), with samples from all positive cases being
retested. Samples that had a confirmatory positive PCR result and a negative
HBsAg result were determined to be from individuals with OBIs. The viral load
was determined by real-time PCR (Kehua Company, Shanghai, China). The
PCR products were sequenced on an ABI Prism 3130X automatic genetic ana-
lyzer (Applied Biosystems), and phylogenetic analyses were performed by the
neighbor-joining method (MEGA software, version 3.1).
Control cohort. The control cohort consisted of a group of HBsAg-positive
individuals matched to the study group only by age and gender. Among this control
group, 30 were prospective blood donors diagnosed with HBV infection, 60 were
asymptomatic carriers, and 60 were individuals with chronic hepatitis. All specimens
were collected from the Xiamen Center for Disease Control and Prevention, Xia-
men, China. The samples were analyzed for serologic markers for HBV, viral loads,
and the HBV genotype. The genetic diversity of the major hydrophilic region
(MHR) in the S gene in HBVs from the controls was assayed and was compared
with that of the MHR in the S gene in HBVs from donors with OBIs.
Statistical evaluation. Statistical analyses were performed by the Mantel-
Haenszel 2 test and Fisher’s exact test for categorical variables and by the
Mann-Whitney analysis of variance test for continuous variables (Open Source
Epidemiologic Statistics for Public Health [OpenEpi], version 2.3). Differences
were considered to be statistically significant when the P values were 0.05. The
demographic data collected included age, gender, and place of birth. The place
of birth was included because the prevalence of HBV varies geographically (30).
RESULTS
Of the 19,518 samples tested, 19,360 tested negative for
HBsAg (by one rapid test and three ELISAs) and 158 sam-
TABLE 1. Different primer pairs used for in-house nested PCR assaya for HBV DNA
Primer set and
type Primer name Sequence (5–3) Position (nt
b) Product length(bp) Target region
A
1st primer set
Sense AF1 5-GTCTGCGGCGTTTTATC-3 419–435 340
Antisense AR1 5-ACAGTGGGGGAAAGC-3 745–759
2nd primer set
Sense AF2 5-TGCCCGTTTGTCCTCTA-3 503–519 199 Small S gene
Antisense AR2 5-AGAAACGGRCTGAGGC-3 687–702 aa 110 to aa165
S
1st primer set
Sense S1 5-CCTGCTGGTGGCTCCAGTTC-3 56–75 751
Antisense S2 5-ATACCCAAAGACAAAAGAAAA-3 827–807
2nd primer set
Sense S3 5-GCGGGGTTTTTCTTGTTGAC-3 203–222 564 Small S gene
Antisense S4 5-GGGACTCAAGATGTTGTACAG-3 787–767 aa 24 to aa 204
Hc
1st primer set
Sense AbF 5-CTGCTATGCCTCATCTTCT-3 454–469 867
Antisense AdR 5-AGGAGTTCCGCAGTATG-3 1305–1321
2nd primer set
Sense AaF 5-CAAGGTATGTTGCCCGTT-3 493–509 238 Small S gene
Antisense AcR 5-ACAAATKGCRCTAGTAAACT-3 712–731 aa 107 to aa 173
Vq
1st primer set
Sense AfF 5- CAGAGTCTAGACTCGTGGT-3 280–298 424
Antisense AbR 5-GAGAAACGGRCTGAGG-3 689–704
2nd primer set
Sense AeF 5- CCCMAAYCTCCARTCACT-3 356–373 300 Small S gene
Antisense AaR 5-GAYGATGGGATGGGAA-3 641–656 aa 62 to aa 150
C
1st primer set
Sense 1763 5-GCTTTGGGGCATGGACATTGACCCGTATAA-3 1763–1792 298
Antisense 2032 5-CTGACTACTAATTCCCTGGATGCTGGGTCT-3 2032–2061
2nd primer set
Sense 1778 5-GACGAATTCCATTGACCCGTATAAAGAATT-3 1778–1807 268 PreC/C gene
Antisense 2017 5-ATGGGATCCCTGGATGCTGGGTCTTCCAAA-3 2017–2046
P
1st primer set
Sense 970F 5-CCTATTGATTGGAAAGTATGTCA-3 970–992 339
Antisense 1309R 5-AGAATGTTTGCTCCAGACC-3 1309–1291
2nd primer set
Sense 970F 5-CCTATTGATTGGAAAGTATGTCA-3 970–992 302 P gene
Antisense 1272R 5-AGTATGGATCGGCAGAGGAG-3 1272–1253 aa634aa721
a The first round of PCR was performed with an outer primer set for 35 cycles (94°C for 40s, 55°C for 40s, and 72°C for 40s). The second round was performed with
an inner primer set for 25 cycles (94°C for 40s, 57°C for 40s, and 72°C for 40s), followed by the extension reaction. Nested PCR products were subjected to
electrophoresis on a 3% agarose gel stained with Sybr green and were visualized with a UV transilluminator.
b nt, number of nucleotides.
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ples tested positive for HBsAg. Of the 158 HBsAg-positive
(HBsAg) samples, only 52 samples were positive by all three
assays, 30 samples were positive by any two assays, and 76
samples were positive by only one assay. Of the 19,360 HBsAg-
negative samples, 995 were positive for anti-HBc alone and 34
of the 995 samples were HBV DNA positive but negative by
all six commercial assays for HBsAg (one colloidal gold im-
munoassay, five ELISAs). Thus, these samples were from in-
dividuals with OBIs and were negative by all six assays for
HBsAg. For all 34 individuals with OBIs, primer set A had the
highest sensitivity; and use of this primer set revealed 30 of 34
positive cases (88%), while 16 cases (47%), 15 cases (44%), 8
cases (24%), 7 cases (21%), and 6 cases (18%) were positive
with primer sets Vq, C, S, P, and Hc, respectively. All individ-
uals with OBIs were clinically asymptomatic and HCV, HIV,
and T. pallidum free and had alanine aminotransferase (ALT)
levels of less than 40 IU/liter. Samples from 4 of the 34 cases
were excluded from sequencing because 2 cases tested positive
by the use of primer set C and 2 cases tested positive by the use
of primer set P, and these two primera set did not target the S
gene, to which primer set A is targeted. The results of sequenc-
ing of the MHR of the S gene are shown in Table 1.
Table 2 compared the birthplaces, ALT levels, virus loads,
HBeAg status, frequency of genotype C, and the mutations lo-
cated in the MHRs of the S gene for the 30 individuals with OBIs
identified, the 30 individuals diagnosed as being HBV carriers at
the time of blood donation (HBsAg donors), the 60 asymptom-
atic carriers not from the blood donor pool, and the 60 hospital-
ized patients with chronic hepatitis. The viral load was signifi-
cantly lower among the donors with OBIs than among the
asymptomatic carriers or patients with chronic hepatitis (P 
0.001 and P  0.001, respectively), but the difference was insig-
nificant when the results for the donors with OBIs were compared
with those for the HBsAg donors (P  0.065).
Phylogenetic analysis indicated that 19 sequences (63.3% [19
of 30]; 95% confidence interval [CI], 43.7 to 80.1%) from
donors with OBIs, 3 sequences (10.0% [3 of 30]; 95% CI, 2.1 to
26.5%) from HBsAg donors, 11 sequences (18.3% [11 of 60];
95% CI, 9.5 to 30.4%) from asymptomatic carriers, and 15
sequences (25.0% [15 of 60]; 95% CI, 14.7 to 37.9%) from
chronic hepatitis patients clustered with HBV genotype C. The
remaining sequences clustered with HBV genotype B. The
prevalence of genotype C was significantly higher than that of
genotype B (P  0.001) in donors with OBIs.
The amino acid map of the S-protein MHR (amino acid [aa]
110 to aa 165) is shown in Fig. 1 and is stratified by HBsAg
status. The average level of amino acid diversity in the a
epitope (aa 124 to aa 147) was significantly higher in the OBI
group than any other control group (P  0.038 for donors with
OBIs versus HBsAg donors, P  0.011 for donors with OBIs
versus asymptomatic carrier groups, P  0.011 for donors with
OBIs versus the group with chronic hepatitis) when amino
acids known to be responsible for the determination of the
serotype were excluded. The samples from the OBI group
showed a significantly higher degree of variability in the region
from aa 110 to aa 123 than the samples from any other
HBsAg group (P 0.005 for donors with OBIs versus HBsAg
donors, P  0.003 for donors with OBIs versus asymptomatic
carriers, P  0.001 for donors with OBIs versus patients with
chronic hepatitis patients). A similar prevalence of mutations
in the region from aa 148 to aa 165 was observed in each group
(Table 1). No insertions or deletions were detected in this
TABLE 2. Comparison of characteristics between the occult HBV cases and other HBV groups
Group
Result for HBsAg-
negative carriers
with OBIs
identified by
testing (n  30)
Result for HBsAg-positive (control) groups
P value (PA, PB, PC)b
HBsAg donorsa
(n  30)
Asymptomatic chronic
carriers (n  60)
Patients with chronic
hepatitis (n  60)
Mean  SD age (yr) 30.4  9.2 30.5  8.6 30.0  8.7 30.5  9.5 Matched
Sex (no. of M:no. of F)c 21:9 21:9 42:18 42:18 Matched
No. (%) of cases with a local
birthplace (Fujian Province)
28 (93.3) 28 (93.3) 59 (98.3) 59 (98.3) 0.99, 0.51, 0.53
Mean  SD HBV DNA load (log
no. of copies/ml)
2.3  0.7 2.9  0.8 4.0  2.0 6.7  1.7 0.065, 0.001,* 0.001*
ALT level (U/liter) All below 40 All below 40 All below 40 813  1173 NC,d NC, 0.001*
No. (%) of cases HBeAg positive 0 (0) 0 (0) 11 (18.3) 36 (60.0) NC, 0.013,* 0.001*
No. (%) of cases infected with
HBV genotype C
19 (63.3) 3 (10.0) 11 (18.3) 15 (25.0) 0.001,* 0.001* 0.001*
No. (%) of cases with mutations
located in the MHR of
HBsAg
a epitope aa 124-147 11 (36.7) 4 (13.3) 8 (13.3) 8 (13.3) 0.038,* 0.011,* 0.011*
aa 124-aa 143 4 (13.3) 4 (13.3) 8 (13.3) 8 (13.3) 0.99, 0.99, 0.99
aa 144-aa 147 9 (30.0) 0 (0) 0 (0) 0 (0) 0.001,* 0.001,* 0.001*
G145R in a epitope 7 (23.3) 0 (0) 0 (0) 0 (0) 0.005,* 0.001,* 0.001*
aa 110-123 7 (23.3) 0 (0) 2 (3.3) 1 (1.7) 0.005,* 0.003,* 0.001*
aa 117-aa 121 7 (23.3) 0 (0) 0 (0) 0 (0) 0.005,* 0.001,* 0.001*
aa 148-aa 165 2 (6.7) 2 (6.7) 2 (3.3) 2 (3.3) 0.99, 0.82, 0.82
a Diagnosed as HBV carriers by testing at the time of blood donation.
b PA, P value for OBI donors versus HBV carriers diagnosed by testing at the time of blood donation; PB, P value for OBI donors versus asymptomatic HBV; PC,
P value for OBI donors versus patients with chronic hepatitis. , statistically significant difference (P  0 0.05).
c M, males; F, females.
d NC, not calculated.
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region. The specific amino acid substitutions in the viruses
from donors with OBIs were concentrated from aa 117 to aa
121 (P  0.005 for donors with OBIs versus HBsAg donors,
P  0.001 for donors with OBIs versus HBsAg asymptomatic
carriers, P  0.001 for donors with OBIs versus HBsAg
chronic hepatitis) and aa 144 to aa 147 (P  0.001 for donors
with OBIs versus HBsAg donors, P  0.001 for donors with
OBIs versus HBsAg asymptomatic carriers, P  0.001 for
donors with OBIs versus HBsAg chronic hepatitis), as indi-
cated by a red box in Fig. 1. Seven mutants (23.3%; 95% CI, 9.9
to 42.3%) with single-point or multipoint G145R mutations
were found in the OBI group, whereas none were found in the
other groups (P  0.001 for donors with OBIs versus asymp-
tomatic carriers and patients with chronic hepatitis, P  0.005
for donors with OBIs versus HBsAg donors).
DISCUSSION
The prevalence of occult HBV infections among non-A
non-E chronic hepatitis cases is a function of several parame-
ters. (i) The method of detection used (ELISA, PCR, or real-
time PCR) affects the prevalence of occult HBV infections
detected. (ii) If the PCR detection method is based, the prim-
ers selected will affect the sensitivity and the specificity of the
test. In our study, six primer sets targeting different regions
yielded sensitivities of between 18% and 88% for the OBI
cohort. (iii) The population being studied affects the preva-
lence of occult HBV infections detected; e.g., the prevalence of
blood donors with anti-HBc is likely to be very different from
the prevalence of patients with chronic hepatitis positive for
HBV DNA. (iv) Patients from areas where HBV is endemic
are more likely to have occult HBV infections, if only because
of the high numbers of infected individuals present. (v) The
materials being tested, e.g., liver tissue or serum, affects the
prevalence of occult HBV infections detected. Occult HBV
infections are more likely to be found when liver tissue spec-
imens than when serum specimens are tested.
The prevalence of OBIs varies greatly. A study from Hong
Kong reported a prevalence rate of 6.9%, while the rate re-
FIG. 1. Amino acid variability of S-protein MHR (aa 110 to aa 165) in individuals with occult HBV infection and controls. The consensus amino
acid sequences of genotypes B and C were deduced from the sequences with GenBank accession numbers AB073826 and AF286594, respectively.
Strains whose amino acid sequences were identical to the wild-type sequence are not represented in the figure. These nonrepresented strains
included the following: OBI 9 to 11, 13 and 14, and 23; HBsAg donors 1, 5 to 8, 10 to 14, 18 and 19, 21, 25, 27 and 28, and 30; asymptomatic
chronic carriers (ASC) 2 and 3, 5 to 8, 12 to 14, 16, 19 to 23, 25 to 27, 29, 31 to 35, 37, 41, 43 to 45, 47 to 49, 51, 54, and 57 to 60; patients with
chronic hepatitis 1, 3 to 7, 9, 11, 15, 17 to 20, 23, 25 to 27, 31 and 32, 34 to 40, 42 to 46, 49, 57, and 60 (genotype B, adw2); donors with OBIs 20,
22, 24, and 26 to 28; HBsAg donors 15, 22, and 23; asymptomatic chronic carriers 4, 10, 11, 17, 24, 36, 39, 42, and 53; and patients with chronic
hepatitis 22, 29, 33, 47 and 48, 51, 53, 55, and 59 (genotype C, adrq positive).
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ported in Italy was 11% (19). Among Canadian Inuits, the rate
was 8.1% among subjects devoid of any HBV markers (22). In
northeast China, the prevalence rates of OBIs in IgG anti-
HBc-positive subjects were 100% (45/45), 86.7% (85/98), and
33.3% (14/42) in patients with cryptogenic chronic liver dis-
ease, HBsAg-negative patients with hepatocellular carcinoma,
and HBsAg-negative healthy people, respectively. In these
cases, the viral load was low (104 viral copies/ml) (9). In
Taiwan, a study that used HBV NAT yielded 12 cases among
10,727 seronegative donations (0.11%) (18). The rate reported
in this paper is 34 of 19,360 HBsAg-negative donations, or
0.18%. The rate of detection is thus dependent on a number of
factors.
In our study, the average age of the donors with OBIs was 30
years; and they had normal ALT levels, undetectable HBeAg,
and very low viral loads. There were more males in the group
that tested positive for anti-HBc only (n  995; ratio of males
to females, 1.8:1) than in either the HBsAg-negative donor
group (n  19,360; ratio of males to females, 1.2:1, P  0.001)
or the HBsAg-positive donor group (n  158; ratio of males to
females, 1.1:1; P  0.008). The HBV genotype associated with
clinical symptoms and disease progression was genotype C.
This genotype is common in East Asian countries and has been
linked with a higher risk of advanced hepatic disease, such as
hepatocellular carcinoma (6, 16). The amino acid substitutions
in the S-protein MHR were found be different in strains from
donors with OBIs than in strains from HBsAg donors. Amino
acid substitutions were detected in the regions from aa 117 to
aa 121 and aa 144 to aa 147 in donors with OBIs (P  0.001)
but not found in strains from HBsAg donors. It is interesting
that these sequences are in the region (aa 119 to aa 124) which
may interfere with hepatitis D virus (HDV) infectivity (14).
HDV particles are coated with the same envelope proteins
(large, middle, and small surface antigens) found in HBV.
HDV is thus considered an occasional satellite of HBV, be-
cause its capacity to propagate depends on the envelope pro-
teins of HBV. If the potential role of aa 119 to aa 124 in the
infectivity of HDV is confirmed for HBV, the high frequency
of mutations in this region might participate in the mechanism
of occurrence of OBIs. The amino acid residues from positions
120 to 123 were considered to be essential for the antigenicity
of HBsAg in previous studies (26). Mutants with mutations
from aa 144 to aa 148, such as G145R and D144A, were
reported to be the common escape mutants that interfered
with HBsAg detection and/or mutants that evaded vaccine-
induced neutralizing antibodies (5, 20). Thus, mutations in
these two regions may have played a crucial role in the occur-
rence of OBIs.
In conclusion, HBV genotype C and specific mutations in
the MHR of the S gene were associated with the occurrence of
occult HBV infection. The clustering of substitutions in the
regions that change the antigenicity of HBsAg and/or virus
infectivity may play a key role in the establishment and/or
maintenance of occult HBV infections.
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